A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Austin, 2004, Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin, Mol. Biol. Cell, 15, 5268, 10.1091/mbc.E04-07-0591 Ben-Kasus, 2009, Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis, Proc. Natl. Acad. Sci. USA, 106, 3294, 10.1073/pnas.0812059106 Boersma, 2011, Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling, J. Biol. Chem., 286, 41273, 10.1074/jbc.M111.293266 Burris, 2011, Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy, J. Clin. Oncol., 29, 398, 10.1200/JCO.2010.29.5865 Cartilage, 2010 Dimasi, 2009, The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators, J. Mol. Biol., 393, 672, 10.1016/j.jmb.2009.08.032 Friedman, 2005, Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy, Proc. Natl. Acad. Sci. USA, 102, 1915, 10.1073/pnas.0409610102 Garratt, 2003, ErbB2 pathways in heart and neural diseases, Trends Cardiovasc. Med., 13, 80, 10.1016/S1050-1738(02)00231-1 Garrett, 2011, Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase, Proc. Natl. Acad. Sci. USA, 108, 5021, 10.1073/pnas.1016140108 Hegde, 2013, Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer, Sci. Transl. Med., 5, 171ra18, 10.1126/scitranslmed.3004438 Huang, 2010, Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay, Am. J. Clin. Pathol., 134, 303, 10.1309/AJCP3BZY4YAFNTRG Junttila, 2009, Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941, Cancer Cell, 15, 429, 10.1016/j.ccr.2009.03.020 Kovtun, 2007, Cell killing by antibody-drug conjugates, Cancer Lett., 255, 232, 10.1016/j.canlet.2007.04.010 Kurata, 2014, Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer, Invest. New Drugs, 32, 946, 10.1007/s10637-014-0112-7 Lambert, 2014, Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer, J. Med. Chem., 57, 6949, 10.1021/jm500766w Lewis Phillips, 2008, Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate, Cancer Res., 68, 9280, 10.1158/0008-5472.CAN-08-1776 Lewis Phillips, 2014, Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy, Clin. Cancer Res., 20, 456, 10.1158/1078-0432.CCR-13-0358 Llombart-Cussac, 2014, A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial, Breast, 23, 656, 10.1016/j.breast.2014.06.017 LoRusso, 2011, Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer, Clin. Cancer Res., 17, 6437, 10.1158/1078-0432.CCR-11-0762 Nordstrom, 2011, Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties, Breast Cancer Res., 13, R123, 10.1186/bcr3069 Pedersen, 2013, A new, highly sensitive IHC test for the detection of HER2 protein in breast cancer (BC) tissue, Cancer Res., 73, 2384, 10.1158/1538-7445.AM2013-2384 Poon, 2013, Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability, Toxicol. Appl. Pharmacol., 273, 298, 10.1016/j.taap.2013.09.003 Press, 1990, Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues, Oncogene, 5, 953 Roepstorff, 2008, Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer, Histochem. Cell Biol., 129, 563, 10.1007/s00418-008-0401-3 Roskoski, 2014, The ErbB/HER family of protein-tyrosine kinases and cancer, Pharmacol. Res., 79, 34, 10.1016/j.phrs.2013.11.002 Sapra, 2013, Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells, Mol. Cancer Ther., 12, 38, 10.1158/1535-7163.MCT-12-0603 Sergina, 2007, Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3, Nature, 445, 437, 10.1038/nature05474 Sievers, 2013, Antibody-drug conjugates in cancer therapy, Annu. Rev. Med., 64, 15, 10.1146/annurev-med-050311-201823 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Sorkin, 2008, Endocytosis and intracellular trafficking of ErbBs, Exp. Cell Res., 314, 3093 Spangler, 2010, Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling, Proc. Natl. Acad. Sci. USA, 107, 13252, 10.1073/pnas.0913476107 Spangler, 2012, Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression, J. Mol. Biol., 422, 532, 10.1016/j.jmb.2012.06.014 Tagliabue, 2010, HER2 as a target for breast cancer therapy, Expert Opin. Biol. Ther., 10, 711, 10.1517/14712591003689972 Tang, 1996, Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells, Cancer Res., 56, 3350 Uppal, 2015, Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1), Clin. Cancer Res., 21, 123, 10.1158/1078-0432.CCR-14-2093 Verma, 2012, Trastuzumab emtansine for HER2-positive advanced breast cancer, N. Engl. J. Med., 367, 1783, 10.1056/NEJMoa1209124 Wiley, 2003, Trafficking of the ErbB receptors and its influence on signaling, Exp. Cell Res., 284, 78, 10.1016/S0014-4827(03)00002-8 Yarden, 2001, Untangling the ErbB signaling network, Nat. Rev. Mol. Cell Biol., 2, 127, 10.1038/35052073 Zhao, 2014, A new Bliss independence model to analyze drug combination data, J. Biomol. Screen, 19, 817, 10.1177/1087057114521867